In August of 2024, the U.S. Department of Health and Human Services began negotiating drug prices for 10 different types of ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

BofA Securities maintained an Underperform rating on shares of Hims & Hers Health, Inc. (NYSE:HIMS) with a steady price ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

Blockbuster weight loss drug Ozempic could get cheaper by 2027, as it's on the list of medications the government is ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...